Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run

A. van Veelen, R. van Geel, R. Schoufs, Y. de Beer, L.M. Stolk, L.E.L. Hendriks, S. Croes*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numbere5224
Number of pages13
JournalBiomedical Chromatography
Volume35
Issue number12
Early online date31 Aug 2021
DOIs
Publication statusPublished - Dec 2021

Keywords

  • LC-MS
  • MS analysis
  • non-small cell lung cancer
  • tyrosine kinase inhibitors
  • validation
  • CELL LUNG-CANCER
  • OPEN-LABEL
  • RAPID-DETERMINATION
  • 1ST-LINE TREATMENT
  • MASS-SPECTROMETRY
  • KINASE INHIBITORS
  • CHEMOTHERAPY
  • AFATINIB

Cite this